The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk

PB Sandesara, SS Virani, S Fazio… - Endocrine …, 2019 - academic.oup.com
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death
worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of …

Exploration and development of PPAR modulators in health and disease: an update of clinical evidence

HS Cheng, WR Tan, ZS Low, C Marvalim… - International journal of …, 2019 - mdpi.com
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the
expression of genes responsible for energy metabolism, cellular development, and …

Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017

M Kinoshita, K Yokote, H Arai, M Iida… - … of atherosclerosis and …, 2018 - jstage.jst.go.jp
Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …

SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways

Y Majeed, N Halabi, AY Madani, R Engelke… - Scientific reports, 2021 - nature.com
The NAD+-dependent deacetylase SIRT1 controls key metabolic functions by deacetylating
target proteins and strategies that promote SIRT1 function such as SIRT1 overexpression or …

Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases

S Yamashita, D Masuda, Y Matsuzawa - Current atherosclerosis reports, 2020 - Springer
Abstract Purpose of Review Reduction of serum low-density lipoprotein cholesterol (LDL-C)
levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) …

Oleuropein: A natural antioxidant molecule in the treatment of metabolic syndrome

J Ahamad, I Toufeeq, MA Khan… - Phytotherapy …, 2019 - Wiley Online Library
Olive (Olea europaea Linn., Fam. Oleaceae) is commonly known as Zaytoon in
Mediterranean region. Its fruits and oil are essential components of Mediterranean diets …

PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients

NF Lange, V Graf, C Caussy, JF Dufour - International journal of …, 2022 - mdpi.com
Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of
the nuclear hormone receptor superfamily, have been identified as key metabolic regulators …

PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α

L Han, WJ Shen, S Bittner, FB Kraemer… - Future Cardiology, 2017 - Future Medicine
This article provides a comprehensive review about the molecular and metabolic actions of
PPAR-α. It describes its structural features, ligand specificity, gene transcription …

Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022

T Okamura, K Tsukamoto, H Arai, Y Fujioka… - … of Atherosclerosis and …, 2024 - jstage.jst.go.jp
In Japan, a super-aged society, deaths from atherosclerotic cardiovascular disease
(ASCVD), especially cardiac diseases including coronary artery disease (CAD) such as …

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia

JC Fruchart - Cardiovascular Diabetology, 2017 - Springer
Despite best evidence-based treatment including statins, residual cardiovascular risk poses
a major challenge for clinicians in the twenty first century. Atherogenic dyslipidaemia, in …